SPGI:NYSES&P Global Inc. Analysis
Data as of 2026-05-27 - not real-time
$414.95
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
S&P Global (SPGI) is trading at $414.95, well above its DCF‑derived fair value of $320.76 and its 20‑day SMA of $418.79, indicating a short‑term overextension. The 14‑day RSI sits at 45.4, suggesting neutral momentum, while the MACD histogram has turned marginally positive, hinting at a tentative bullish signal amid an overall bearish trend. Valuation metrics are stretched: the forward PE of 18.7 is still above the industry average PE of 16.6, and the price‑to‑book of 3.94 exceeds the sector norm. Volatility remains elevated at 22.5% over the past 30 days, though beta is low at 0.50, reflecting limited systematic risk. Fundamentally, the company delivers robust performance with 10.4% revenue growth, a 70.5% gross margin, and a 44.3% operating margin, supported by strong free cash flow of $5.30 bn and a modest payout ratio of 24%. Recent material news highlights a $2 bn private senior notes offering and a $2.5 bn financing round ahead of a planned spinoff, providing potential upside catalysts. The dividend of $0.97 (0.94% yield) remains sustainable given the healthy cash flow and low payout. Taken together, the stock appears overvalued in the near term but possesses strong underlying fundamentals and dividend appeal for longer horizons.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price trading above short‑term moving averages
- Neutral RSI and marginal MACD bullishness
- Overvaluation relative to DCF and peers
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Strong revenue growth and high profit margins
- Sustainable dividend with low payout ratio
- Potential catalyst from new financing and upcoming spinoff
Long Term
> 3 yearsNeutral
Model confidence: 7/10
Key Factors
- Durable competitive moat in financial data and ratings
- Consistent free cash flow generation
- Attractive dividend yield for income‑focused investors
Key Metrics & Analysis
Financial Health
Revenue Growth10.40%
Profit Margin30.36%
P/E Ratio26.3
ROE13.94%
ROA6.92%
Debt/Equity38.39
P/B Ratio3.9
Op. Cash Flow$5.7B
Free Cash Flow$5.3B
Industry P/E16.6
Technical Analysis
TrendBearish
RSI45.4
Support$401.00
Resistance$438.88
MA 20$418.79
MA 50$424.83
MA 200$479.50
MACDBullish
VolumeIncreasing
Fear & Greed Index91.93
Valuation
Fair Value$320.76
Target Price$533.76
Upside/Downside28.63%
GradeOvervalued
TypeGrowth
Dividend Yield0.94%
Risk Assessment
Beta0.50
Volatility22.54%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.